A new Cochrane review has concluded that anti-amyloid Alzheimer's drugs provide no meaningful clinical benefit to patients while heightening risks of brain swelling and bleeding. The analysis of 17 studies involving over 20,000 patients found the clinical effect of these medications to be trivial or absent, challenging recent trial successes and sparking debate among experts and charities. The Cochrane review examined 17 studies involving 20,342 patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, providing a comprehensive assessment of available evidence.
Anti-amyloid drugs work by binding to amyloid protein in the brain to clear deposits and slow cognitive decline, representing a theoretical approach to treating Alzheimer's disease. However, this conclusion contradicts recent trial successes with donanemab and lecanemab, which showed they could slow the pace of cognitive decline, marking the first time any drug slowed brain destruction in Alzheimer's. Charities have disputed the Cochrane review findings, arguing it unfairly combines failed drug trials with recent successful ones.
Some experts say the Cochrane review is fundamentally flawed because it groups older experimental drugs with newer proven ones, blurring the evidence. Lecanemab and donanemab are currently licensed for use in the UK, but the NHS rejected the treatments after NICE ruled their benefits too small to warrant the cost. An 18-month course of these drugs would cost about £90,000 privately, making them inaccessible to most patients without NHS coverage.
The specific side effect rates associated with brain swelling and bleeding from these drugs remain unclear, requiring further investigation. Long-term impacts beyond 18 months on cognitive decline and quality of life are also unknown, as most trials have been relatively short-term. How cost-effectiveness analyses by health authorities other than NICE evaluate these drugs is another unknown, with international approaches varying significantly.
What alternative treatments or research directions are currently being explored for Alzheimer's represents an active area of investigation, including non-amyloid targets and combination therapies. How patient and caregiver experiences with these drugs compare to the clinical trial data remains uncertain, highlighting the gap between research findings and real-world outcomes.